Aclaris advances ATI-052 after positive Phase 1a results

Aclaris Therapeutics ( (ACRS) ) just unveiled an announcement.

On January 6, 2026, Aclaris Therapeutics reported positive interim data from a first-in-human Phase 1a single and multiple ascending dose trial of its bispecific antibody ATI-052 in healthy adults, showing the drug was well tolerated up to 720 mg with mostly mild, self-resolving injection site reactions and no serious adverse events or discontinuations. The study demonstrated a potentially best-in-class pharmacokinetic profile with an effective half-life of at least 26 days and dose-proportional exposure, alongside robust pharmacodynamic effects including strong target engagement and sustained inhibition of key inflammatory markers at low doses, supporting the possibility of dosing as infrequently as once every three months. On the back of these results, the company moved to rapidly advance ATI-052’s development, planning imminent initiation of Phase 1b proof-of-concept trials in atopic dermatitis and asthma in the first quarter of 2026, with top-line data expected in the second half of 2026 and a Phase 2b trial in atopic dermatitis slated to start in the same period, potentially strengthening Aclaris’s position in the competitive immunology and allergy market if later-stage trials confirm these early findings.

The most recent analyst rating on (ACRS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.

Spark’s Take on ACRS Stock

According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.

The score is held back primarily by weak financial performance (deep losses, declining TTM revenue, and cash burn), partially offset by a strong low-leverage balance sheet. Technicals are moderately supportive with price above key longer-term averages, while valuation is constrained by negative earnings and no dividend. A positive corporate update (R&D Day and stated runway into 2028) adds support but does not fully offset operating risk.

To see Spark’s full report on ACRS stock, click here.

More about Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel product candidates for patients with immuno-inflammatory diseases who lack satisfactory treatment options, leveraging a multi-stage R&D-driven pipeline targeting atopic, immunologic and respiratory conditions.

Average Trading Volume: 1,280,919

Technical Sentiment Signal: Buy

Current Market Cap: $287.1M

See more data about ACRS stock on TipRanks’ Stock Analysis page.